BGLC earnings analysis
What we found in BGLC's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The supplied filing text does not include current-quarter revenue, EPS, margin, balance-sheet or cash-flow amounts, preventing a quantitative earnings-trend assessment. Operationally, VitaGuard agreements are executed, but the platform had generated $0 of revenue as of June 30, 2026 and remains subject to verification, validation and regulatory readiness. The most material negatives are the continuing ineffective controls and material weakness at Chemrex, the unresolved approximately $2,944,000 recovery claim, and issuance of 516,128 compensatory shares.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- VitaGuard agreements executed
- The VitaGuard transaction agreements, including the IPTA and License Agreement, have been executed. However, the filing states that VitaGuard had not generated revenue for the Company as of June 30, 2026.
- Internal-control remediation underway
- Management implemented significant remediation measures at Chemrex, including changes to policies, documentation, personnel and delegated authorities, and expects to continue implementation and testing during fiscal 2026.
- Equity compensation issued
- The Company issued 516,128 fully vested shares on August 13, 2026 as compensation for completed services, with an aggregate Board-approved value of $799,998.40.
- Share count increased materially
- The August 13 share issuance increased issued and outstanding shares from 2,417,314 to 2,933,442, a dilution of 516,128 shares, while 77,504 shares remained available under the equity plan.
- CEO appointment renewed
- The CEO and President was reappointed for a term beginning September 1, 2026 and ending August 31, 2029, with a gross base salary of $35,000 per month.
- Lead director compensation raised
- Chee Keong Yap was designated Lead Independent Director, and his total monthly director compensation increased by $700 from $1,800 to $2,500.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- VitaGuard launch and revenue risk
- The Company disclosed a new risk that VitaGuard commercialization depends on post-closing verification, intellectual-property perfection, validation, regulatory preparation and operational readiness. As of June 30, 2026, the platform had generated $0 of revenue for the Company, and the filing states that remaining work could delay or prevent revenue, adoption or profitability.
- Material internal-control weakness persists
- Disclosure controls and internal control over financial reporting were concluded to be ineffective as of June 30, 2026 because of a material weakness at Chemrex. Review and ratification of certain affected transactions remained ongoing, and remediation will not be complete until controls have operated and been tested for a sufficient period.
- Recovery claim remains unresolved
- The Company issued Letters of Demand seeking approximately $2,944,000 from five former Chemrex officers and directors for alleged unauthorized payments made from July 2024 through August 2025. No court or tribunal proceeding had commenced as of the filing date, so recovery remains uncertain.
- Management equity awards dilute holders
- The August 13, 2026 equity awards included 338,709 shares to the CEO valued at $524,998.95 and 96,774 shares to the CFO valued at $149,999.70, increasing the outstanding share count to 2,933,442.
What they said about what is next.
No quantitative revenue or EPS outlook was provided in the filing. Management stated it expects to continue implementing and testing internal-control remediation measures during fiscal 2026; VitaGuard had not generated revenue as of June 30, 2026.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 15, 2026
- BioNexus Gene Lab Corp. (BGLC) reported a significant decline in revenues, recording $22,842 for Q1 2026, down 98.93% compared to $2,137,075 in Q1 2025. The company's gross margin turned negative at -3.46%, reflecting…
- 10-K · April 14, 2026
- BioNexus Gene Lab (BGLC) operates two core businesses: Chemrex (chemical raw material distribution in Southeast Asia) and MRNA Scientific (blood-based genomic screening). The company executed an ASEAN-exclusive,…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing BGLC makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever